Five-year adjuvant treatment of women with breast cancer positive for estrogen receptors (ERs) with tamoxifen reduces breast cancer mortality of about one third every year, irrespectively from age, use of chemotherapy, progesterone receptor status, or other tumor characteristics [1]. The gene discussed is PGR; the disease is breast carcinoma.